Christian Berne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Berne has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
A. Dahlgren
Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
1 shared publicationA.-C. Syvänen
Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
1 shared publication- Annica Siewert-Delle
AstraZeneca Sverige AB, Sweden
1 shared publication B. Zethelius
Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
1 shared publicationK. Jensevik
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
1 shared publication- Kurt Svärdsudd
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 30 March 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 194
Efficacy of screening for high blood pressure in dental health care
There is consensus on the importance of early detection and treatment of high blood pressure. Dental care is one of few medical services to which a considerable proportion of the general population comes for regular check-ups. We tested the effects of blood pressure screening in dental care centres with subsequent work-up of subjects screening positive in primary health care (PHCC).
- 30 March 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 194
Open AccessEfficacy of screening for high blood pressure in dental health care
There is consensus on the importance of early detection and treatment of high blood pressure. Dental care is one of few medical services to which a considerable proportion of the general population comes for regular check-ups. We tested the effects of blood pressure screening in dental care centres with subsequent work-up of subjects screening positive in primary health care (PHCC).
- 25 December 2010
- Vol. 107 (45) , 2815-9
[Intensive efforts for future antidiabetic agents].
- 6 July 2007
- Published by Springer Nature in Diabetologia
- Vol. 50 (9) , 1852-1857
Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men
- 6 July 2007
- Published by Springer Nature in Diabetologia
- Vol. 50 (9) , 1852-1857
Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men
- Open Access
- 3 June 2005
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 4 (1) , 7
Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
Objective: The Use of Rosuvastatin versus Atorvastatin iN type 2 diabetes mellitUS (URANUS) study compared rosuvastatin with atorvastatin for the reduction of low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes.Methods: After a 6-week dietary run-in, patients aged ≥ 18 years with type 2 diabetes and LDL-C ≥ 3.3 mmol/L were randomised to double-blind treatment with rosuvastatin 10 mg (n = 232) or atorvastatin 10 mg (n = 233) for 4 weeks. Doses were then titrated up to a maximum of rosuvastatin 40 mg or atorvastatin 80 mg over 12 weeks to achieve the 1998 European LDL-C goal (<3.0 mmol/L).Results: Rosuvastatin reduced LDL-C levels significantly more than atorvastatin during the fixed-dose and titration periods (p < 0.0001). Significantly more patients reached the 1998 LDL-C goal with rosuvastatin 10 mg compared with atorvastatin 10 mg at 4 weeks (81% vs 65%, p < 0.001). At 16 weeks, significantly more patients achieved their LDL-C goal with rosuvastatin compared with atorvastatin (94% vs 88%, p < 0.05) and more patients receiving rosuvastatin remained at their starting dose with reduced requirement for dose titration. At 4 weeks, 65% of rosuvastatin patients had reached their 2003 European LDL-C goal (< 2.5 mmol/L), compared with 33% of atorvastatin patients (p < 0.0001). Both treatments were similarly well tolerated with no unexpected safety concerns.Conclusion: At the start dose and following dose titration, rosuvastatin was significantly more effective than atorvastatin at reducing LDL-C and achieving European LDL-C goals in patients with type 2 diabetes.
- 3 June 2005
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 4 (1) , 7
Open AccessComparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
Objective: The Use of Rosuvastatin versus Atorvastatin iN type 2 diabetes mellitUS (URANUS) study compared rosuvastatin with atorvastatin for the reduction of low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes.Methods: After a 6-week dietary run-in, patients aged ≥ 18 years with type 2 diabetes and LDL-C ≥ 3.3 mmol/L were randomised to double-blind treatment with rosuvastatin 10 mg (n = 232) or atorvastatin 10 mg (n = 233) for 4 weeks. Doses were then titrated up to a maximum of rosuvastatin 40 mg or atorvastatin 80 mg over 12 weeks to achieve the 1998 European LDL-C goal (<3.0 mmol/L).Results: Rosuvastatin reduced LDL-C levels significantly more than atorvastatin during the fixed-dose and titration periods (p < 0.0001). Significantly more patients reached the 1998 LDL-C goal with rosuvastatin 10 mg compared with atorvastatin 10 mg at 4 weeks (81% vs 65%, p < 0.001). At 16 weeks, significantly more patients achieved their LDL-C goal with rosuvastatin compared with atorvastatin (94% vs 88%, p < 0.05) and more patients receiving rosuvastatin remained at their starting dose with reduced requirement for dose titration. At 4 weeks, 65% of rosuvastatin patients had reached their 2003 European LDL-C goal (< 2.5 mmol/L), compared with 33% of atorvastatin patients (p < 0.0001). Both treatments were similarly well tolerated with no unexpected safety concerns.Conclusion: At the start dose and following dose titration, rosuvastatin was significantly more effective than atorvastatin at reducing LDL-C and achieving European LDL-C goals in patients with type 2 diabetes.
- 25 January 2005
- Published by Wiley in Diabetic Medicine
- Vol. 22 (5) , 612-618
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
Aims To assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes.Methods Patients treated with either metformin alone or metformin in combination with sulphonylurea were randomized to double‐blind treatment with orlistat or placebo (120 mg) three times daily, combined with a mildly reduced calorie diet and a weight management programme for 52 weeks. Changes in body weight, anthropometry, glycaemic control and lipid profile were assessed.Results After 52 weeks, orlistat‐treated patients achieved an almost threefold greater reduction in weight compared with placebo recipients (−5.0% vs. −1.8%; P < 0.0001). The decrease in waist circumference was significantly greater with orlistat than placebo (−4.8 cm vs. −2.8 cm; P = 0.0022). Orlistat treatment was also associated with significantly greater reductions in haemoglobin A1c (−1.1% vs. −0.2%; P < 0.0001), fasting plasma glucose (−1.9 mmol/l vs. −0.3 mmol/l; P < 0.0001), total cholesterol (−0.2 mmol/l vs. 0.1 mmol/l; P = 0.03) and apolipoprotein B (−0.08 g/l vs. 0.01 g/l; P = 0.0085) and greater improvements in beta‐cell function (P = 0.031) and insulin resistance (P = 0.001) assessed using the homeostasis model assessment (HOMA). Similar results were obtained for subgroups of patients treated with metformin alone or metformin in combination with sulphonylurea. Orlistat treatment reduced the requirement for anti‐diabetic medication more than placebo.Conclusions Orlistat, in combination with a reduced calorie diet and a weight management programme, promotes weight loss and clinically relevant improvements in glycaemic control and other cardiovascular risk factors in obese patients with Type 2 diabetes.
- 25 January 2005
- Published by Wiley in Diabetic Medicine
- Vol. 22 (5) , 612-618
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
Aims To assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes.Methods Patients treated with either metformin alone or metformin in combination with sulphonylurea were randomized to double‐blind treatment with orlistat or placebo (120 mg) three times daily, combined with a mildly reduced calorie diet and a weight management programme for 52 weeks. Changes in body weight, anthropometry, glycaemic control and lipid profile were assessed.Results After 52 weeks, orlistat‐treated patients achieved an almost threefold greater reduction in weight compared with placebo recipients (−5.0% vs. −1.8%; P < 0.0001). The decrease in waist circumference was significantly greater with orlistat than placebo (−4.8 cm vs. −2.8 cm; P = 0.0022). Orlistat treatment was also associated with significantly greater reductions in haemoglobin A1c (−1.1% vs. −0.2%; P < 0.0001), fasting plasma glucose (−1.9 mmol/l vs. −0.3 mmol/l; P < 0.0001), total cholesterol (−0.2 mmol/l vs. 0.1 mmol/l; P = 0.03) and apolipoprotein B (−0.08 g/l vs. 0.01 g/l; P = 0.0085) and greater improvements in beta‐cell function (P = 0.031) and insulin resistance (P = 0.001) assessed using the homeostasis model assessment (HOMA). Similar results were obtained for subgroups of patients treated with metformin alone or metformin in combination with sulphonylurea. Orlistat treatment reduced the requirement for anti‐diabetic medication more than placebo.Conclusions Orlistat, in combination with a reduced calorie diet and a weight management programme, promotes weight loss and clinically relevant improvements in glycaemic control and other cardiovascular risk factors in obese patients with Type 2 diabetes.